Novomics, founded in 2010, is a pioneering company in the Health Care industry, based in South Korea. The company's primary focus lies in gene-based molecular diagnosis, with a relentless pursuit of becoming the leader in this field. Collaborating with researchers, clinical physicians, and pharmaceutical companies, Novomics is dedicated to enhancing the understanding of cancer gene analysis for the advancement of precision medicine. This focus ultimately aims to provide molecular diagnostic treatment for the standard care of cancer patients. In a significant milestone, Novomics secured a notable KRW1.00B Series C investment on 01 January 2017, with Stonebridge Ventures stepping in as the investor. This injection of funds is poised to fuel the company's ongoing quest to uncover new target genes and accumulate clinical experiences, ultimately contributing to the betterment of cancer patients' lives.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | KRW1.00B | 1 |
|
01 Jan 2017 |
| Series B | KRW500.00M | 1 |
|
01 Dec 2016 |
| Pre Seed Round | Unknown | 1 | TIPS Program | 01 Dec 2013 |
No recent news or press coverage available for Novomics.
We care about your data, and we'd love to use cookies make your experience better.
